N🟁N

TrovaGene, Inc., Announce Issuance of U.S. Patent for Diagnosis and Monitoring of Pathogenic Infection

  //house-home.news-articles.net/content/2010/10/1 .. osis-and-monitoring-of-pathogenic-infection.html
  Published in House and Home on Wednesday, October 13th 2010 at 4:10 GMT by Market Wire
          ^{🞛 This publication is a summary or evaluation of another publication}

SAN DIEGO--([ BUSINESS WIRE ])--TrovaGene, Inc. (Pink Sheets:TROV), a developer of transrenal molecular diagnostics to facilitate personalized medicine, received notice of U.S. Patent 7,803,929 entitled aKits for diagnosis and monitoring of pathogenic infection by analysis of cell-free pathogenic nucleic acids in urine.a

"Kits for diagnosis and monitoring of pathogenic infection by analysis of cell-free pathogenic nucleic acids in urine."

aWe believe that this patent is a valuable addition to our extremely broad IP estate,a commented Dr. David Robbins, TrovaGenea™s Vice President of Research and Development. aIt provides a basis for diagnosing and monitoring bacterial or parasitic infections using a sample that is stable, easy to collect, and truly non-invasive.

Patent 7,803,929 complements the previously issued U.S. patents including the reissued patent RE39,920 which covers detection of nucleic acids from viral, bacterial, fungal, mycoplasma, and protozoan infections in urine samples.

About TrovaGene, Inc. (Pink Sheets:TROV) | [ www.trovagene.com ])

Headquartered in San Diego, California, TrovaGene has focused on development of tests using its patented transrenal nucleic acid technology. Transrenal DNA and RNA are short nucleic acid fragments from normal cell death that cross the kidney barrier and can be detected in urine. Safe and simple urine collection can replace biopsy or blood sampling and has a broad range of applications, including tumor detection and monitoring, infectious disease detection, prenatal testing, tissue transplantation, genetic testing for forensic identity determination, drug development, and research to counter bioterrorism. The TrovaGene molecular diagnostics assays will provide information that will enable physicians to provide personalized medical care for their patients.

TrovaGene has a dominant patent position as it relates to transrenal molecular testing. It has issued U.S. and European patents that cover testing for molecular targets that pass through the kidney. In addition to these core patents it has numerous patent applications pending in the areas of cancer, infectious diseases, transplantation, prenatal and genetic testing.

Statements about TrovaGene's expectations, applications of its technology, markets, and other statements that are not historical facts are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on management's current beliefs, assumptions, estimates and projections. Actual results may differ materially from those projected in the forward-looking statements for various reasons, including risks associated with product development, government regulation, market acceptance, and dependence on key personnel, obtaining financing and other factors.